Renoprotective effect of combining angiotensin Ii receptor blockers and statins in diabetic rats
Gao, P.; Jia, R.-h.; Yang, D.-p.; Liu, H.-y.; Song, E.-f.; Chu, G.-l.; Ding, G.-h.
Chinese Medical Journal 118(7): 598-602
2005
ISSN/ISBN: 0366-6999 PMID: 15820093 Document Number: 585160
Document emailed within 1 workday
Related Documents
Aoyama, N. 2007: Effect of combination therapy with angiotensin Ii type i receptor and aldosterone receptor blockers in heart failure Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 5): 145-149Egido, J.; Ruiz-Ortega, M.; Muñoz-García, B.; Martín-Ventura, J.L.; Blanco-Colio, L.M. 2005: Vasoprotective effects of statins and angiotensin Ii blockers in atherothrombosis Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 25(Suppl 2): 117-128
Kovács, T. 2014: The effect of angiotensin receptor blockers in cerebrovascular disorders and dementia: bonus in addition to the antihypertensive effect Ideggyogyaszati Szemle 67(5-6): 149-168
Surabenjawong, U.; Thunpiphat, N.; Chatsiricharoenkul, S.; Monsomboon, A. 2013: Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers Journal of the Medical Association of Thailand 96(8): 905-910
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin converting enzyme inhibitors and angiotensin Ii receptor blockers on angiogenesis of gastric cancer in a nude mouse model Zhonghua Wei Chang Wai Ke Za Zhi 11(6): 565-568
Wang, L.; Cai, S.-r.; Zhang, C.-h.; He, Y.-l.; Zhan, W.-h.; Wu, H.; Peng, J.-j. 2008: Effects of angiotensin-converting enzyme inhibitors and angiotensin Ii type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model Chinese Medical Journal 121(21): 2167-2171
Vijan, S.G. 2009: Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients Journal of the Indian Medical Association 107(3): 178-182
Katayama, S. 2005: Renoprotective effect of Blood pressure control on progression of diabetic retinopathies Nihon Rinsho. Japanese Journal of Clinical Medicine 63 Suppl. 6: 389-393
Lapchyns'ka, I.I.; Zhurylo, T.I.; Seliuk, M.M.; Hromova, A.I. 2002: Renoprotective effect of monopril in patients with diabetes mellitus in the preclinical stage of diabetic nephropathy Likars'ka Sprava 2002(5-6): 91-93
Lommi, J. 2005: Angiotensin II-receptor blockers Duodecim; Laaketieteellinen Aikakauskirja 121(6): 589-592
Oyebola, D.D.; Ariwodola, J.O. 1985: Effect of adrenergic receptor blockers on the cardio-respiratory response to cow's urine concoction in rats African Journal of Medicine and Medical Sciences 14(1-2): 11-19
Sabbah, Z.A.; Mansoor, A.; Kaul, U. 2013: Angiotensin receptor blockers - advantages of the new sartans Journal of the Association of Physicians of India 61(7): 464-470
Fruhwald, F.M.; Kickenweiz, E.; Zweiker, R.; Klein, W. 2001: Angiotensin i receptor blockers for heart failure Wiener Medizinische Wochenschrift 151(7-8): 157-159
Oganov, R.G.; Nebieridze, D.V. 2002: Metabolic effects of angiotensin-Ii receptor blockers Kardiologiia 42(3): 35-39
Ol'binskaia, L.I.; Morozov, I.A. 1996: Angiotensin-Ii receptor blockers in the treatment of arterial hypertension Eksperimental'naia i Klinicheskaia Farmakologiia 59(5): 76-80
Kumar, S.; Ram, C.V.S. 2007: Angiotensin receptor blockers: current status and future prospects Indian Heart Journal 59(6): 443-453
Raatikainen, M.J.; Huikuri, H.V. 2003: Are ACE inhibitors and angiotensin receptor blockers useful in the treatment of atrial fibrillation? Duodecim; Laaketieteellinen Aikakauskirja 119(16): 1505-1507
Shevtsov, M.I. 2000: Angiotensin Ii receptor blockers - pilot experience and nephrology perspectives Terapevticheskii Arkhiv 72(6): 73-79
Diskin, C.J.; Stokes, T.J.; Dansby, L.M.; Radcliff, L.; Carter, T.B. 2007: Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker? Journal of Nephrology 20(4): 410-416
Spinar, J.; Vítovec, J.; Soucek, M.; Dusek, L.; Pavlík, T. 2009: CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin Ii receptor blockers Vnitrni Lekarstvi 55(5): 481-488